European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
Subscribe To Our Newsletter & Stay Updated